Seeing Is Believing
Currently out of the existing stock ratings of Kostas Biliouris, 32 are a BUY (76.19%), 10 are a HOLD (23.81%).
Analyst Kostas Biliouris, currently employed at BMO, carries an average stock price target met ratio of 24.12% that have a potential upside of 19.69% achieved within 95 days.
Kostas Biliouris’s has documented 87 price targets and ratings displayed on 13 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NTLA, Intellia Therapeutics at 10-Jan-2025.
Analyst best performing recommendations are on BEAM (BEAM THERAPEUTICS ).
The best stock recommendation documented was for BEAM (BEAM THERAPEUTICS ) at 7/18/2022. The price target of $61 was fulfilled within 1 day with a profit of $2.99 (5.15%) receiving and performance score of 51.54.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$25
$7.94 (46.54%)
$31
1 months 13 days ago
(07-May-2025)
9/10 (90%)
$8.77 (54.04%)
158
Buy
$55
$37.94 (222.39%)
$78
1 months 13 days ago
(07-May-2025)
0/4 (0%)
$38.77 (238.88%)
Buy
$70
$52.94 (310.32%)
$105
1 months 13 days ago
(07-May-2025)
0/3 (0%)
$53.77 (331.30%)
Buy
$80
$62.94 (368.93%)
$80
2 months 13 days ago
(07-Apr-2025)
0/8 (0%)
$64.7 (422.88%)
Buy
3 months 8 days ago
(12-Mar-2025)
1/10 (10%)
$12.38 (46.51%)
118
Which stock is Kostas Biliouris is most bullish on?
Which stock is Kostas Biliouris is most reserved on?
What Year was the first public recommendation made by Kostas Biliouris?